Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Low Anterior Resection Syndrome 1Diarrhea 1Colitis 1Breast Neoplasms 1

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1Therapeutics 1Radiosurgery 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1Geriatric Assessment 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fecal Microbiota Transplantation 1Exercise 1Continuous Positive Airway Pressure 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Loperamide × 90 days × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡